Cognitive enhancers as a treatment for heroin relapse and addiction.


Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
03 2019
Historique:
received: 26 09 2018
revised: 22 12 2018
accepted: 14 01 2019
pubmed: 18 1 2019
medline: 24 8 2019
entrez: 18 1 2019
Statut: ppublish

Résumé

Heroin addiction is a disorder that stems from maladaptive plasticity within neural circuits and produces broad cognitive deficits. Despite considerable advances in psychotherapy and pharmacotherapy for heroin relapse and addiction, effective treatments for heroin use disorder are still lacking. Increasing preclinical evidence indicates that heroin seeking behavior is persistent after withdrawal, while cognitive dysfunctions associated with chronic heroin use are an important contributing factor to risk of heroin relapse and addiction. Cognitive enhancers may be used to stimulate treatment success and enhance treatment efficacy. The purpose of this review is to outline the literature that demonstrates the cognitive deficits during the development of heroin addiction and withdrawal process, and several factors that underline the efficacy of cognitive enhancers for heroin use disorders. The review, then, examines the potential use and pharmacological mechanisms of cognitive enhancers that act on cholinergic, glutamatergic, dopaminergic or adrenergic pathways. It also examines the effects of compounds that alter CREB signaling and epigenetic mechanisms in animal model of heroin relapse. The current body of research reveals the new insights into the pharmacological mechanisms underlying heroin addiction and holds a significant promise for cognitive enhancers as an improved approach to treat heroin use disorder in a more efficient and persistent way.

Identifiants

pubmed: 30654135
pii: S1043-6618(18)31464-6
doi: 10.1016/j.phrs.2019.01.025
pii:
doi:

Substances chimiques

Nootropic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

378-383

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Baomiao Ma (B)

Zhejiang Provincial Key Lab of Addiction, Ningbo University School of Medicine, Ningbo 315211, PR China; Wuhan Institutes of Biomedical Sciences, Jianghan University, Wuhan 430056, PR China.

Disen Mei (D)

Zhejiang Provincial Key Lab of Addiction, Ningbo University School of Medicine, Ningbo 315211, PR China.

Fangmin Wang (F)

Zhejiang Provincial Key Lab of Addiction, Ningbo University School of Medicine, Ningbo 315211, PR China; Lab. of Behavioral Neuroscience, Ningbo Addiction Research and Treatment Center, Ningbo University School of Medicine, Ningbo 315010, PR China.

Yu Liu (Y)

Zhejiang Provincial Key Lab of Addiction, Ningbo University School of Medicine, Ningbo 315211, PR China.

Wenhua Zhou (W)

Zhejiang Provincial Key Lab of Addiction, Ningbo University School of Medicine, Ningbo 315211, PR China; Lab. of Behavioral Neuroscience, Ningbo Addiction Research and Treatment Center, Ningbo University School of Medicine, Ningbo 315010, PR China. Electronic address: whzhou@vip.163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH